This activity is supported by an educational grant from Genentech.
Management of Patients with Chemotherapy - Induced Nausea and Vomiting
Sally Yowell Barbour, Pharm D, BCOP, CPP
Duke University Hospital
The first 5-HT3 antagonist was approved in 1991 for the management of chemotherapy-induced nausea and vomiting (CINV), leading to moving more chemotherapy regimens to the outpatient setting and improving adherence to treatment. Since then, several 5-HT3 antagonists and NK-1 receptor antagonists have been added to the armamentarium. Despite advances, CINV is often inadequately prevented and/or managed. This learning activity reviews current evidence-based interventions for the prevention and management of CINV, including physiologic mechanisms associated with CINV, strategies to target the pathways involved in CINV, and recommended guidelines.
These CE/CME/CEU accredited activities are jointly provided by